MétaCan
Menu
← Back to cohort
Record W4383535274 · doi:10.1136/bmjopen-2023-072347

Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial

2023· article· en· W4383535274 on OpenAlexaff
H. B. Hutchins, John Bradley, Elizabeth Pretorius, Eunice Teixeira da Silva, Hristina Vasileva, Robert T. Jones, Mamadou Ousmane Ndiath, Harouna M Soumaré, David Mabey, Ernesto Nante, Cesário Martins, James G. Logan, Hannah Slater, Chris Drakeley, Umberto D’Alessandro, Amabélia Rodrigues, Anna Last

Bibliographic record

VenueBMJ Open · 2023
Typearticle
Languageen
FieldMedicine
TopicMalaria Research and Control
Canadian institutionsPrograms for Assessment of Technology in Health Research Institute
FundersForeign, Commonwealth and Development OfficeMedical Research CouncilNational Institute for Health and Care ResearchWellcome Trust
KeywordsMedicineIvermectinMalariaMass drug administrationPopulationPlasmodium falciparumArtemisininEnvironmental healthVeterinary medicineImmunology

Abstract

fetched live from OpenAlex

Introduction As malaria declines, innovative tools are required to further reduce transmission and achieve elimination. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) is capable of reducing malaria transmission where coverage of control interventions is already high, though the impact is short-lived. Combining ACT with ivermectin, an oral endectocide shown to reduce vector survival, may increase its impact, while also treating ivermectin-sensitive co-endemic diseases and minimising the potential impact of ACT resistance in this context. Methods and analysis MATAMAL is a cluster-randomised placebo-controlled trial. The trial is being conducted in 24 clusters on the Bijagós Archipelago, Guinea-Bissau, where the peak prevalence of Plasmodium falciparum ( Pf ) parasitaemia is approximately 15%. Clusters have been randomly allocated to receive MDA with dihydroartemisinin–piperaquine and either ivermectin or placebo. The primary objective is to determine whether the addition of ivermectin MDA is more effective than dihydroartemisinin–piperaquine MDA alone in reducing the prevalence of P. falciparum parasitaemia, measured during peak transmission season after 2 years of seasonal MDA. Secondary objectives include assessing prevalence after 1 year of MDA; malaria incidence monitored through active and passive surveillance; age-adjusted prevalence of serological markers indicating exposure to P. falciparum and anopheline mosquitoes; vector parous rates, species composition, population density and sporozoite rates; prevalence of vector pyrethroid resistance; prevalence of artemisinin resistance in P. falciparum using genomic markers; ivermectin’s impact on co-endemic diseases; coverage estimates; and the safety of combined MDA. Ethics and dissemination The trial has been approved by the London School of Hygiene and Tropical Medicine’s Ethics Committee (UK) (19156) and the Comite Nacional de Eticas de Saude (Guinea-Bissau) (084/CNES/INASA/2020). Results will be disseminated in peer-reviewed publications and in discussion with the Bissau-Guinean Ministry of Public Health and participating communities. Trial registration number NCT04844905 .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.028
metaresearch head score (Gemma)0.030
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.128
Threshold uncertainty score0.427

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0280.030
Meta-epidemiology (narrow)0.0080.004
Meta-epidemiology (broad)0.0130.005
Bibliometrics0.0030.003
Science and technology studies0.0040.005
Scholarly communication0.0050.004
Open science0.0040.002
Research integrity0.0090.010
Insufficient payload (model declined to judge)0.1280.027

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.090
GPT teacher head0.428
Teacher spread0.337 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations16
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueBMJ Open→Same topicMalaria Research and Control→French-language works237,207→